{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:11:32Z","timestamp":1791353492618,"version":"4.3.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s11912-023-01382-9","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T23:48:51Z","timestamp":1679874531000},"page":"539-547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Clonal Hematopoiesis of Indeterminate Potential: Current Understanding and Future Directions"],"prefix":"10.1007","volume":"25","author":[{"given":"Inderpreet","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"issue":"1","key":"1382_CR1","first-page":"9","volume":"126","author":"DP Steensma","year":"2015","unstructured":"Steensma DP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood J Am Soc Hematol. 2015;126(1):9\u201316.","journal-title":"Blood J Am Soc Hematol"},{"issue":"6","key":"1382_CR2","first-page":"742","volume":"130","author":"F Zink","year":"2017","unstructured":"Zink F, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood J Am Soc Hematol. 2017;130(6):742\u201352.","journal-title":"Blood J Am Soc Hematol"},{"issue":"26","key":"1382_CR3","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488\u201398.","journal-title":"N Engl J Med"},{"issue":"2","key":"1382_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111\u201321.","journal-title":"N Engl J Med"},{"key":"1382_CR5","doi-asserted-by":"publisher","first-page":"100587","DOI":"10.1016\/j.blre.2019.100587","volume":"37","author":"JP Bewersdorf","year":"2019","unstructured":"\u2022 Bewersdorf JP, et al. From clonal hematopoiesis to myeloid leukemia and what happens in between: will improved understanding lead to new therapeutic and preventive opportunities? Blood Rev. 2019;37:100587. This review discusses the clonal hematopoiesis including definition, pathogenesis, adverse outcomes, and need of clinical follow up.","journal-title":"Blood Rev"},{"key":"1382_CR6","doi-asserted-by":"publisher","first-page":"e2100309","DOI":"10.1200\/PO.21.00309","volume":"6","author":"A Singh","year":"2022","unstructured":"\u2022\u2022 Singh A, et al. Mutant PPM1D-and TP53-driven hematopoiesis populates the hematopoietic compartment in response to peptide receptor radionuclide therapy. JCO Precis Oncol. 2022;6:e2100309. This study highlights the pathogenesis and development of clonal hematopoiesis following cytotoxic therapy involving peptide receptor radionuclide therapy.","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"1382_CR7","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41591-018-0114-7","volume":"24","author":"RS Sellar","year":"2018","unstructured":"Sellar RS, Jaiswal S, Ebert BL. Predicting progression to AML. Nat Med. 2018;24(7):904\u20136.","journal-title":"Nat Med"},{"issue":"1","key":"1382_CR8","first-page":"264","volume":"2018","author":"DP Steensma","year":"2018","unstructured":"Steensma DP. Clinical consequences of clonal hematopoiesis of indeterminate potential. Hematol 2014 Am Soc Hematol Educ Program Book. 2018;2018(1):264\u20139.","journal-title":"Hematol 2014 Am Soc Hematol Educ Program Book"},{"issue":"4","key":"1382_CR9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jacc.2019.06.007","volume":"74","author":"P Libby","year":"2019","unstructured":"\u2022\u2022 Libby P, et al. Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC review topic of the week. J Am Coll Cardiol. 2019;74(4):567\u201377. This editorial highlights the pathogenesis of cardiovascular risk associated with clonal hematopoiesis and approach of CH in cardiology clinics.","journal-title":"J Am Coll Cardiol"},{"issue":"7714","key":"1382_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","volume":"559","author":"S Abelson","year":"2018","unstructured":"Abelson S, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559(7714):400\u20134.","journal-title":"Nature"},{"issue":"3","key":"1382_CR11","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","volume":"21","author":"CC Coombs","year":"2017","unstructured":"Coombs CC, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell stem cell. 2017;21(3):374-382. e4.","journal-title":"Cell stem cell"},{"issue":"2","key":"1382_CR12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","volume":"150","author":"JS Welch","year":"2012","unstructured":"Welch JS, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264\u201378.","journal-title":"Cell"},{"issue":"3","key":"1382_CR13","first-page":"357","volume":"139","author":"PG Miller","year":"2022","unstructured":"Miller PG, et al. Association of clonal hematopoiesis with chronic obstructive pulmonary disease. Blood J Am Soc Hematol. 2022;139(3):357\u201368.","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"1382_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.118.038434","volume":"139","author":"A Aviv","year":"2019","unstructured":"Aviv A, Levy D. Hemothelium, clonal hematopoiesis of indeterminate potential, and atherosclerosis: role of telomere length dynamics. Circulation. 2019;139(1):7\u20139.","journal-title":"Circulation"},{"issue":"1","key":"1382_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-02858-0","volume":"9","author":"TN Wong","year":"2018","unstructured":"Wong TN, et al. Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nat Commun. 2018;9(1):1\u201310.","journal-title":"Nat Commun"},{"issue":"1","key":"1382_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamacardio.2018.3965","volume":"4","author":"L Dorsheimer","year":"2019","unstructured":"Dorsheimer L, et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 2019;4(1):25\u201333.","journal-title":"JAMA Cardiol"},{"issue":"8","key":"1382_CR17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1093\/eurheartj\/ehz591","volume":"41","author":"S Mas-Peiro","year":"2020","unstructured":"Mas-Peiro S, et al. Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation. Eur Heart J. 2020;41(8):933\u20139.","journal-title":"Eur Heart J"},{"key":"1382_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.exphem.2020.01.011","volume":"83","author":"EK Cook","year":"2020","unstructured":"Cook EK, Luo M, Rauh MJ. Clonal hematopoiesis and inflammation: partners in leukemogenesis and comorbidity. Exp Hematol. 2020;83:85\u201394.","journal-title":"Exp Hematol"},{"issue":"1","key":"1382_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.celrep.2018.03.025","volume":"23","author":"M Jeong","year":"2018","unstructured":"Jeong M, et al. Loss of Dnmt3a immortalizes hematopoietic stem cells in vivo. Cell Rep. 2018;23(1):1\u201310.","journal-title":"Cell Rep"},{"issue":"3","key":"1382_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/CIRCRESAHA.118.313225","volume":"123","author":"S Sano","year":"2018","unstructured":"Sano S, Oshima K, Wang Y, Katanasaka Y, Sano M, Walsh K. CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease. Circ Res. 2018;123(3):335\u201341.","journal-title":"Circ Res"},{"issue":"8","key":"1382_CR21","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.stem.2021.03.002","volume":"28","author":"D Hormaechea-Agulla","year":"2021","unstructured":"Hormaechea-Agulla D, et al. Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFN\u03b3 signaling. Cell Stem Cell. 2021;28(8):1428-1442. e6.","journal-title":"Cell Stem Cell"},{"issue":"2","key":"1382_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1161\/CIRCRESAHA.120.317104","volume":"128","author":"WT Abplanalp","year":"2021","unstructured":"Abplanalp WT, et al. Clonal hematopoiesis\u2013driver DNMT3A mutations alter immune cells in heart failure. Circ Res. 2021;128(2):216\u201328.","journal-title":"Circ Res"},{"issue":"6327","key":"1382_CR23","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1126\/science.aag1381","volume":"355","author":"JJ Fuster","year":"2017","unstructured":"Fuster JJ, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327):842\u20137.","journal-title":"Science"},{"issue":"11","key":"1382_CR24","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1161\/CIRCRESAHA.118.313283","volume":"123","author":"W Wang","year":"2018","unstructured":"Wang W, et al. Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2 V617F mice. Circ Res. 2018;123(11):e35\u201347.","journal-title":"Circ Res"},{"issue":"7853","key":"1382_CR25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41586-021-03341-5","volume":"592","author":"TP Fidler","year":"2021","unstructured":"Fidler TP, et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature. 2021;592(7853):296\u2013301.","journal-title":"Nature"},{"key":"1382_CR26","doi-asserted-by":"crossref","unstructured":"Libby P, Molinaro R, Sellar RS, Ebert BL. Jak-ing up the plaque\u2019s lipid core\u2026 and even more, 123, ed: Am Heart Assoc 2018;1180\u20131182.","DOI":"10.1161\/CIRCRESAHA.118.314074"},{"issue":"10","key":"1382_CR27","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1038\/s41375-020-0896-8","volume":"34","author":"AA Dawoud","year":"2020","unstructured":"Dawoud AA, Tapper WJ, Cross NC. Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking. Leukemia. 2020;34(10):2660\u201372.","journal-title":"Leukemia"},{"issue":"2","key":"1382_CR28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/jha2.101","volume":"1","author":"MG Faber","year":"2020","unstructured":"Faber MG, et al. Predictors of vascular disease in myelodysplastic syndromes. eJHaem. 2020;1(2):467\u201372.","journal-title":"eJHaem"},{"key":"1382_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cancergen.2017.01.002","volume":"211","author":"B Coffee","year":"2017","unstructured":"Coffee B, et al. Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene pan cancer panel. Cancer Genet. 2017;211:5\u20138.","journal-title":"Cancer Genet"},{"issue":"1","key":"1382_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.6004\/jnccn.2017.0007","volume":"15","author":"PL Greenberg","year":"2017","unstructured":"Greenberg PL, et al. Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(1):60\u201387.","journal-title":"J Natl Compr Canc Netw"},{"issue":"18","key":"1382_CR31","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1158\/1078-0432.CCR-18-0143","volume":"24","author":"Y Hu","year":"2018","unstructured":"Hu Y, et al. False-positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res. 2018;24(18):4437\u201343.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"1382_CR32","first-page":"2501","volume":"131","author":"EA Severson","year":"2018","unstructured":"Severson EA, et al. Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. Blood J Am Soc Hematol. 2018;131(22):2501\u20135.","journal-title":"Blood J Am Soc Hematol"},{"issue":"11","key":"1382_CR33","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jamaoncol.2018.2297","volume":"4","author":"RN Ptashkin","year":"2018","unstructured":"Ptashkin RN, et al. Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors. JAMA Oncol. 2018;4(11):1589\u201393.","journal-title":"JAMA Oncol"},{"issue":"5","key":"1382_CR34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1200\/JCO.2018.79.2184","volume":"37","author":"M Frick","year":"2019","unstructured":"Frick M, et al. Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2019;37(5):375\u201385.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1382_CR35","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.hoc.2019.11.006","volume":"34","author":"KL Bolton","year":"2020","unstructured":"\u2022\u2022 Bolton KL, et al. The clinical management of clonal hematopoiesis: creation of a clonal hematopoiesis clinic. Hematol Oncol Clin. 2020;34(2):357\u201367. This editorial highlights the need of close follow-up for clonal hematopoiesis with multidisciplinary clinics to understand the potential outcomes.","journal-title":"Hematol Oncol Clin"},{"issue":"1","key":"1382_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.18.00331","volume":"37","author":"KL Bolton","year":"2019","unstructured":"Bolton KL, et al. Managing clonal hematopoiesis in patients with solid tumors. J Clin Oncol. 2019;37(1):7.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1382_CR37","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1001\/jamacardio.2020.1271","volume":"5","author":"R Sidlow","year":"2020","unstructured":"Sidlow R, et al. The clinical challenge of clonal hematopoiesis, a newly recognized cardiovascular risk factor. JAMA Cardiol. 2020;5(8):958\u201361.","journal-title":"JAMA Cardiol"},{"issue":"9","key":"1382_CR38","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamacardio.2021.1678","volume":"6","author":"R Bhattacharya","year":"2021","unstructured":"\u2022 Bhattacharya R, et al. Association of diet quality with prevalence of clonal hematopoiesis and adverse cardiovascular events. JAMA Cardiol. 2021;6(9):1069\u201377. ()","journal-title":"JAMA Cardiol"},{"issue":"5","key":"1382_CR39","doi-asserted-by":"publisher","first-page":"e018789","DOI":"10.1161\/JAHA.120.018789","volume":"10","author":"B Haring","year":"2021","unstructured":"\u2022 Haring B, et al. Healthy lifestyle and clonal hematopoiesis of indeterminate potential: results from the Women\u2019s Health Initiative. J Am Heart Assoc. 2021;10(5):e018789. This editorial highlights healthy lifestyle as a modifiable risk factor of clonal hematopoiesis.","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"1382_CR40","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med"},{"issue":"Suppl_1","key":"1382_CR41","first-page":"A15111","volume":"138","author":"EC Svensson","year":"2018","unstructured":"Svensson EC, et al. TET2-driven clonal hematopoiesis predicts enhanced response to canakinumab in the CANTOS trial: an exploratory analysis. Circulation. 2018;138(Suppl_1):A15111\u2013A15111.","journal-title":"Circulation"},{"issue":"18","key":"1382_CR42","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","volume":"70","author":"P Libby","year":"2017","unstructured":"Libby P. Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Am Coll Cardiol. 2017;70(18):2278\u201389.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1382_CR43","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.119.044362","volume":"141","author":"AG Bick","year":"2020","unstructured":"Bick AG, et al. Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis. Circulation. 2020;141(2):124\u201331.","journal-title":"Circulation"},{"issue":"6","key":"1382_CR44","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.cell.2017.07.032","volume":"170","author":"L Cimmino","year":"2017","unstructured":"Cimmino L, et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell. 2017;170(6):1079-1095. e20.","journal-title":"Cell"},{"issue":"12","key":"1382_CR45","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s00277-017-3161-0","volume":"96","author":"S Nassereddine","year":"2017","unstructured":"Nassereddine S, Lap CJ, Haroun F, Tabbara I. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia. Ann Hematol. 2017;96(12):1983\u201391.","journal-title":"Ann Hematol"},{"issue":"9","key":"1382_CR46","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/ng.2700","volume":"45","author":"A Bonnefond","year":"2013","unstructured":"Bonnefond A, et al. Association between large detectable clonal mosaicism and type 2 diabetes with vascular complications. Nat Genet. 2013;45(9):1040\u20133.","journal-title":"Nat Genet"},{"issue":"4","key":"1382_CR47","doi-asserted-by":"publisher","first-page":"108326","DOI":"10.1016\/j.celrep.2020.108326","volume":"33","author":"JJ Fuster","year":"2020","unstructured":"Fuster JJ, et al. TET2-loss-of-function-driven clonal hematopoiesis exacerbates experimental insulin resistance in aging and obesity. Cell Rep. 2020;33(4):108326.","journal-title":"Cell Rep"},{"key":"1382_CR48","doi-asserted-by":"crossref","unstructured":"Niroula A, Belizaire R. \"Clonal hematopoiesis and CKD progression,\" ed: Am Soc Nephrol, 2022.","DOI":"10.1681\/ASN.2022030262"},{"issue":"2","key":"1382_CR49","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1161\/STROKEAHA.121.037388","volume":"29","author":"R Bhattacharya","year":"2022","unstructured":"Bhattacharya R, et al. Clonal hematopoiesis is associated with higher risk of stroke. Stroke. 2022;29(2):788\u201397.","journal-title":"Stroke"},{"key":"1382_CR50","unstructured":"Wong WJ, et al. Clonal hematopoiesis and risk of chronic liver disease. medRxiv 2022."},{"issue":"7","key":"1382_CR51","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.tem.2020.02.005","volume":"31","author":"MK Lee","year":"2020","unstructured":"Lee MK, Dragoljevic D, Veiga CB, Wang N, Yvan-Charvet L, Murphy AJ. Interplay between clonal hematopoiesis of indeterminate potential and metabolism. Trends Endocrinol Metab. 2020;31(7):525\u201335.","journal-title":"Trends Endocrinol Metab"},{"issue":"03","key":"1382_CR52","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1055\/s-0041-1733856","volume":"5","author":"S Soudet","year":"2021","unstructured":"Soudet S, Jedraszak G, Evrard O, Marolleau J, Garcon L, Pietri MS. Is hematopoietic clonality of indetermined potential a risk factor for pulmonary embolism? TH Open. 2021;5(03):e338\u201342.","journal-title":"TH Open"},{"issue":"5","key":"1382_CR53","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1681\/ASN.2021060774","volume":"33","author":"C Vlasschaert","year":"2022","unstructured":"Vlasschaert C, et al. Association of clonal hematopoiesis of indeterminate potential with worse kidney function and anemia in two cohorts of patients with advanced chronic kidney disease. J Am Soc Nephrol. 2022;33(5):985\u201395.","journal-title":"J Am Soc Nephrol"},{"key":"1382_CR54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1182\/blood-2021-151064","volume":"138","author":"H Bouzid","year":"2021","unstructured":"Bouzid H, et al. Clonal hematopoiesis is associated with reduced risk of Alzheimer\u2019s disease. Blood. 2021;138:5.","journal-title":"Blood"},{"issue":"2","key":"1382_CR55","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1200\/JCO.21.02286","volume":"40","author":"CJ Gibson","year":"2022","unstructured":"Gibson CJ, et al. Donor clonal hematopoiesis and recipient outcomes after transplantation. J Clin Oncol. 2022;40(2):189\u2013201.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1382_CR56","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1128\/MCB.00776-13","volume":"33","author":"SL Peters","year":"2013","unstructured":"Peters SL, et al. Essential role for Dnmt1 in the prevention and maintenance of MYC-induced T-cell lymphomas. Mol Cell Biol. 2013;33(21):4321\u201333.","journal-title":"Mol Cell Biol"},{"issue":"9","key":"1382_CR57","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/cas.12484","volume":"105","author":"H Nakajima","year":"2014","unstructured":"Nakajima H, Kunimoto H. TET2 as an epigenetic master regulator for normal and malignant hematopoiesis. Cancer Sci. 2014;105(9):1093\u20139.","journal-title":"Cancer Sci"},{"issue":"11","key":"1382_CR58","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/leu.2009.141","volume":"23","author":"N Carbuccia","year":"2009","unstructured":"Carbuccia N, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23(11):2183\u20136.","journal-title":"Leukemia"},{"issue":"1","key":"1382_CR59","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.gde.2006.12.009","volume":"17","author":"JN Ihle","year":"2007","unstructured":"Ihle JN, Gilliland DG. Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev. 2007;17(1):8\u201314.","journal-title":"Curr Opin Genet Dev"},{"issue":"5","key":"1382_CR60","doi-asserted-by":"publisher","first-page":"a026062","DOI":"10.1101\/cshperspect.a026062","volume":"6","author":"BJ Aubrey","year":"2016","unstructured":"Aubrey BJ, Strasser A, Kelly GL. Tumor-suppressor functions of the TP53 pathway. Cold Spring Harb Perspect Med. 2016;6(5):a026062.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"1382_CR61","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/ng894","volume":"31","author":"DV Bulavin","year":"2002","unstructured":"Bulavin DV, et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet. 2002;31(2):210\u20135.","journal-title":"Nat Genet"},{"issue":"9","key":"1382_CR62","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nchembio.2007.18","volume":"3","author":"D Kaida","year":"2007","unstructured":"Kaida D, et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol. 2007;3(9):576\u201383.","journal-title":"Nat Chem Biol"},{"issue":"5","key":"1382_CR63","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","volume":"27","author":"E Kim","year":"2015","unstructured":"Kim E, et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell. 2015;27(5):617\u201330.","journal-title":"Cancer Cell"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01382-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-023-01382-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01382-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T08:21:49Z","timestamp":1683361309000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-023-01382-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1382"],"URL":"https:\/\/doi.org\/10.1007\/s11912-023-01382-9","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"assertion":[{"value":"16 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}